The First Hospital Of Anhui Medical University
Welcome,         Profile    Billing    Logout  
 13 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gu, Kangsheng
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated
3
89
RoW
Icaritin, Sorafenib Tosylate Tablets
Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital
Hepatocellular Carcinoma (HCC)
02/22
02/22
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting
3
738
RoW
TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive Small Cell Lung Cancer
12/22
12/22
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting
3
531
RoW
JS001, Nab-Paclitaxel, Placebo
Shanghai Junshi Bioscience Co., Ltd.
Triple-Negative Breast Cancer
12/24
12/25
PRESERVE-003, NCT05671510: ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruiting
3
600
Europe, Canada, US, RoW
Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere
OncoC4, Inc., BioNTech SE
Non Small Cell Lung Cancer
06/26
06/27
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recruiting
2
100
RoW
Toripalimab, Tuoyi
Shanghai Junshi Bioscience Co., Ltd.
Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy
12/22
03/23
NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors

Terminated
2
86
RoW
Envofolimab, BD0801, Docetaxel, Irinotecan, Leucovorin calcium, 5-Fluorouridine
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor
07/23
07/23
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
NCT05249244: A Real World Study of the Treatment of Gastric Adenocarcinoma With Huachansu

Active, not recruiting
N/A
1000
RoW
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma
12/21
02/22
Shao, Min
NCT06051513: Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

Recruiting
N/A
360
RoW
treatment with or without colistin
Southeast University, China
Carbapenem-Resistant Enterobacteriaceae Infection
07/25
11/25
Du, Yingying
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting
3
518
RoW
TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
08/25
12/25
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Active, not recruiting
2
133
RoW
TJ107 +Pembrolizumab
TJ Biopharma Co., Ltd.
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
06/24
12/24
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting
2
52
RoW
SPH4336 Tablets
Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer Brain Metastases
12/25
12/25
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations

Recruiting
1/2
290
RoW
GFH375
Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutations, Advanced Solid Tumors
07/28
12/28
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Active, not recruiting
1/2
376
RoW
TJ004309, Toripalimab
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
12/24
12/24

Download Options